PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including t… Read more
PolyPeptide Group AG (PPGN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.150x
Based on the latest financial reports, PolyPeptide Group AG (PPGN) has a cash flow conversion efficiency ratio of 0.150x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF49.66 Million) by net assets (CHF330.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PolyPeptide Group AG - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how PolyPeptide Group AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PolyPeptide Group AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PolyPeptide Group AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guilin Seamild Foods Co Ltd
SHE:002956
|
0.086x |
|
Bio-Thera Solutions Ltd
SHG:688177
|
-0.124x |
|
Kenmec Mechanical Engineering Co Ltd
TWO:6125
|
-0.039x |
|
Stolt-Nielsen Limited
PINK:SOIEF
|
0.058x |
|
Zhejiang He Chuan Technology Corp. Ltd. A
SHG:688320
|
N/A |
|
Industrial Logistics Properties Trust
NASDAQ:ILPT
|
0.025x |
|
Triductor Technology (Suzhou) Inc.
SHG:688259
|
0.022x |
|
Ciputra Development Tbk
JK:CTRA
|
0.033x |
Annual Cash Flow Conversion Efficiency for PolyPeptide Group AG (2018–2024)
The table below shows the annual cash flow conversion efficiency of PolyPeptide Group AG from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF357.24 Million | CHF89.40 Million | 0.250x | +161.48% |
| 2023-12-31 | CHF381.23 Million | CHF36.48 Million | 0.096x | +639.13% |
| 2022-12-31 | CHF421.68 Million | CHF5.46 Million | 0.013x | -90.49% |
| 2021-12-31 | CHF421.17 Million | CHF57.35 Million | 0.136x | -51.11% |
| 2020-12-31 | CHF177.66 Million | CHF49.48 Million | 0.279x | -25.15% |
| 2019-12-31 | CHF149.42 Million | CHF55.60 Million | 0.372x | +139.51% |
| 2018-12-31 | CHF147.67 Million | CHF22.94 Million | 0.155x | -- |